Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate

Cancer Biol Ther. 2011 Feb 1;11(3):368-70. doi: 10.4161/cbt.11.3.14696. Epub 2011 Feb 1.

Authors

Toni M Brand¹, Deric L Wheeler

Affiliation

¹ Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

PMID: 21228636
DOI: 10.4161/cbt.11.3.14696

No abstract available

Publication types

Comment

MeSH terms

Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics
Citrates / therapeutic use*
Class I Phosphatidylinositol 3-Kinases
ErbB Receptors / genetics*
ErbB Receptors / metabolism
Female
Humans
Phosphatidylinositol 3-Kinases / genetics*
Phosphatidylinositol 3-Kinases / metabolism
Prognosis

Substances

Citrates
lithium citrate
Phosphatidylinositol 3-Kinases
Class I Phosphatidylinositol 3-Kinases
PIK3CA protein, human
ErbB Receptors